Aptamer's Optimer technology achieves key milestones in genetic medicine delivery, enhancing targeting specificity and ...

A genetic medicines customer has selected the company’s binders for commercial development of the customer’s product. Aptamer Group announced on Nov. 7, 2024 that one of its customers has advanced use ...

York-based biotech firm Aptamer Group has secured new contracts worth almost £500,000 with leading pharmaceutical companies.

Zentek, through its wholly-owned subsidiary Triera Biosciences Ltd., has a global exclusive license to the aptamer-based platform technology developed by McMaster University, which is being jointly ...

York biotech firm, Aptamer Group, has secured new contracts worth up to £471,000. In a commercial trading update the company reports it is "continuing the positive commercial traction" of the past ...

Yorkshire life sciences company Aptamer has narrowed its losses after saying it made commercial and technical strides in ...

Aptamer Group, a developer of novel Optimer® binders to enable innovation in the life sciences industry, says it has extended ...

Consequently, Aptamer Group is well-positioned moving into the new financial year, with ongoing work progressing through the lab and a robust sales pipeline. Strong technical delivery across ...

KUALA LUMPUR, Malaysia, Oct. 23, 2024 /PRNewswire/ -- BIOGENES TECHNOLOGIES launches the world's first aptamer-based histochemistry staining product developed using its proprietary ...